Obesity is associated with diseases such as dyslipidemia, type 2 diabetes, and cardiovascular disease (CVD). The accumulation of lipids in numerous tissues is accompanied by increased infl ammatory processes such as macrophage infi ltration and production of infl ammatory mediators in Abstract Low-grade infl ammation in different tissues, including activation of the nuclear factor B pathway in liver, is involved in metabolic disorders such as type 2 diabetes and cardiovascular diseases (CVDs). In this study, we investigated the relation between chronic hepatocyte-specifi c overexpression of IkB kinase (IKK)- and hypertriglyceridemia, an important risk factor for CVD, by evaluating whether activation of IKK- only in the hepatocyte affects VLDL-triglyceride (TG) metabolism directly. Transgenic overexpression of constitutively active human IKK- specifi cally in hepatocytes of hyperlipidemic APOE*3-Leiden mice clearly induced hypertriglyceridemia. Mechanistic in vivo studies revealed that the hypertriglyceridemia was caused by increased hepatic VLDL-TG production rather than a change in plasma VLDL-TG clearance. Studies in primary hepatocytes showed that IKK- overexpression also enhances TG secretion in vitro, indicating a direct relation between IKK- activation and TG production within the hepatocyte. Hepatic lipid analysis and hepatic gene expression analysis of pathways involved in lipid metabolism suggested that hepatocyte-specifi c IKK- overexpression increases VLDL production not by increased steatosis or decreased FA oxidation, but most likely by carbohydrate-responsive element binding protein-mediated upregulation of Fas expression. These fi ndings implicate that specifi c activation of infl ammatory pathways exclusively within hepatocytes induces hypertriglyceridemia. Furthermore, we identify the hepatocytic IKK- pathway as a possible target to treat hypertriglyceridemia. Abbreviations: Abcg5 , ATP-binding cassette sub-family G member 5; Abcg8 , ATP-binding cassette sub-family G member 8; Acox1 , acylCoenzyme A oxidase 1; apo, apolipoprotein; ChREBP, carbohydrateresponsive element binding protein; Cidea , cell death activator CIDE-A; Cidec , fat-specifi c protein FSP27; Cpt1a , carnitine palmitoyltransferase 1a; CVD, cardiovascular disease; Cyclo , cyclophilin; Cyp27a1 , cholesterol 27 hydroxylase; Cyp7a1 , cholesterol 7 alpha hydroxylase; Cyp8b1 , sterol 12 alpha-hydrolase; Dgat1 , acyl:diacylglycerol transferase 1; E3L, APOE*3-Leiden; FAME, fatty acid methyl ester; Fas , fatty acid synthase; FPLC, fast-performance liquid chromatography; Gapdh , glyceraldehyde-3-phosphate dehydrogenase; Hmgcr , HMG-CoA reductase; I B, inhibitor of B; IKK- , I B kinase  ; LIKK, liver-specifi c IKK- overexpression; Mttp , microsomal triglyceride transfer protein; NF-B, nuclear factor-B; Nr1 h3 , liver X receptor alpha; Nr1 h4 , farnesoid X activated receptor; Pklr, liver-type pyruvate kinase; PL, phospholipid; Plin2 , perilipin 2; Plin5 , perilipin 5; Ppara , peroxisome proliferator activated receptor alpha; Ppargc...